Jump to content

Meet the Genedata
Biopharma Community

Genedata Biopharma Partner Symposium | Boston, MA, USA | March 9–10, 2023

The Genedata Biopharma Partner Symposium is a unique interdisciplinary event at the interface between biopharma R&D and IT. Presentations and discussions will focus on innovative applications and new industry requirements: novel molecular formats (e.g., multispecifics, TCRs, CARs, AAVs, RNA vaccines), advanced screening technologies, MS-based multi-attribute methods (MAM), NGS, molecular patient profiling, and automation and data FAIRification in biopharmaceutical R&D.

At this invitation-only event, leading biopharma companies will show how groups have set up, operate, and use Genedata solutions to transform their biotherapeutics research & development and how this results in increased efficiency and throughput. The symposium brings together people working in all areas of biopharma:

  • Discovery—Screening, selection, engineering, and validation
  • Development—Characterization, optimization, and cell-line engineering
  • Production—Bioprocessing, biosafety, and QC
  • Translational Science—Patient profiling and integrative (pre-)clinical research
  • IT—Infrastructure, networking, and integration
  • Automation—Laboratory, data and research process automation

The event includes plenary keynote presentations as well as targeted break-out sessions and poster and demo sessions which highlight how the Genedata Biopharma Platform is streamlining processes and increasing efficiency throughout biopharmaceutical research, development, and production.

In addition to the scientific program, there will be an evening social networking event and dinner.

Agenda

Day 1 — Thursday, March 9, 2023 
Plenary Session
8:30–9:00Registration & Welcome Coffee
Koumentzelis Auditorium, Lindsay Hall, 3rd Floor, Bentley University, 175 Forest St, Waltham, MA, USA
9:00–9:10Opening Remarks 
Jana Hersch, Head of Corporate Scientific Engagement, Genedata, Boston, MA, USA
9:10–9:30Digitalization of Biopharma R&D, Machine Learning, AI – Quo Vadis?
Othmar Pfannes, CEO, Genedata, Basel, Switzerland
9:30–10:00Synergies Within and Beyond the Genedata Biopharma Platform at Novartis
Barbara Brannetti, Director, Data Science, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, USA
10:00–10:30Pfizer’s mRNA Workflows for Vaccine and Therapeutic Discovery
Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA
10:30–11:00Break
11:00–11:30Gilead’s Biologics Journey and Genedata
Nathan Thomsen, Director – Protein Therapeutics, Gilead Sciences Inc., Foster City, CA, USA
Epic Ding, Sr. IT Business Systems Domain Manager, Gilead Sciences Inc., Foster City, CA, USA
11:30–12:00Gaining Translational Insights from Real-World and Single-Cell Data
Guoqiang Zhang, Associate Director Translational Bioinformatics, Astellas Pharma, Cambridge, MA, USA
12:00–12:30Better Biologics by Design - Paving the Way Towards Advanced High-Throughput Mass Spectrometry to Safeguard the Discovery & Optimization of Multispecific Biotherapeutics at Sanofi
Soraya Hölper, Project Manager, Sanofi, Frankfurt, Germany
12:30–2:00Lunch
LaCava Center, 3rd Floor, Executive Dining Room  (Room 395)
Breakout Sessions
 BIOLOGICS
Biotherapeutics
Discovery		BIOPROCESS
Bioprocess Development		SCREENER
Assay Analysis & Management		EXPRESSIONIST
Mass Spectrometry Data Analysis		PROFILER
Translational & Clinical Research		SELECTOR
NGS-Based Development & Biosafety
2:00–2:30

AstraZeneca’s Genedata Biologics Journey
Gilad Kaplan, Associate Director, Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA

Genedata Bioprocess Deployment & Use at Janssen 
Robert Hepler, Principal Scientist, Janssen, Spring House, PA, USA		Integration of Genedata Screener at Genentech
Eric Torres, Senior Systems Specialist, Genentech, South San Francisco, CA, USA		Using Mass Spectrometry to Assist with the Discovery and Development of Cell and Gene Therapies
Michael McKinnon, Scientist, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, USA		The Implementation of Genedata Profiler within EMD Serono – Insights from a Bioinformatician
Nicholas Geraci, Exploratory Immunology Bioinformatics, EMD Serono Inc., Billerica, MA, USA		Structural Analysis of Random Transgene Integration in CHO Manufacturing Cell Lines by Targeted Sequencing

Benjamin Lindner, Senior Data Scientist, Boehringer Ingelheim, Biberach, Germany

2:30–3:00Genedata Biologics at Takeda: High-Throughput Protein Production Workflows
Prashanth Vishwanath, Associate Director, Global Biologics, Takeda, Cambridge, MA, USA		Connecting Cell Line Development and Research: Merging Genedata Bioprocess and Biologics Into an E2E Platform at Sanofi
Drew Lynch, Digital Biologics Informatician and Team Lead, Sanofi, Cambridge, MA, USA		A Genedata Training Journey
Frank Kilty, IS Informatics Science Senior Manager, AstraZeneca, Waltham, MA, USA		Increasing Throughput by Automating the Data Analysis of LCMS-UV-CAD Data of Small Molecules
Huy Nguyen, Scientist, Genentech, South San Francisco, CA, USA		Empowering Data Scientists with a High-Performance Environment for Big Data Exploratory Analysis
Takeshi Saito, Director Bioinformatician Translational Science, Astellas Pharma, Cambridge, MA, USA		Genedata Selector Product Roadmap
Ben Adamczyk, Product Management, Selector, Genedata, Boston, MA, USA
3:00–3:30Pfizer’s Use of Plasmid Combinations to Enable Automation for Transient Transfection
Lijian Yu, Senior Principal Scientist, Pfizer, Cambridge, MA, USA

Modelling Cell Line Development with Genedata and Umetrics
Norman Trapp, Head of Digital Solutions, Sartorius BPS, Göttingen, Germany

Screener++: Turbocharging Screener To Reach the Higher Hanging Fruit in Drug and Ion Channel Discovery
Samuel Bradberry, Principal Scientist - Data Analysis, Axxam, Milan, Italy		Using a MAM-Based Workflow to Support Development of a New Bioprocessing Tool
Trina Mouchahoir, Research Chemist, National Institute of Standards and Technology, Gaithersburg, MD, USA		Improving Data FAIRness with Genedata Profiler's Data Inventory
Hareesh Chandrupatla, Data Scientist Leader, Genmab, Princeton, NJ, USA

Panel Discussion: Adventitious Agent Detection – From Method Development to Validation
Nasrin Salehi, Principal Scientist/Group Leader, BioTherapeutics PharmSci, Analytical R&D, Pfizer, Andover, MA, USA

Jürgen Müllberg Associate Director, Bristol Myers Squibb, Devens, MA, USA

Qiu Ruan, Scientific Consultant, Selector, Genedata, Boston, MA, USA

3:30–4:00Evolution of NBE Discovery using Genedata Biologics: from Adoption to Streamlining Lab Automation 
Sameh Eid, Principal Scientist, Merck KGaA, Darmstadt, Germany


Veit Ulshöfer, Global Head of Research and Lab Informatics,  Merck KGaA, Darmstadt, Germany

Genedata Bioprocess Product Roadmap
Christoph Freiberg, Head of Science, Biologics, Genedata, Basel, Switzerland

Balancing Scientific Agility and Mature Data Management in Early-Stage Biotech R&D
Kate Hardy, Director, Informatics and Technology, MOMA Therapeutics, Cambridge, MA, USA		Extended Q&A Discussion / Roundtable DiscussionThe Integration of Next-Generation Sequencing Data with Clinical Trial Data Using Genedata Profiler
Patrick Kaminker, Director Translational Biology, MacroGenics Inc., Rockville, MD, USA
4:00–5:30Demo and Poster Session
Meet the Experts – Check out our demos and view posters. Demos are approximately 5–10 minutes and will be repeated on demand throughout the session.
5:30–8:00Dinner
LaCava Center, 3rd Floor, Executive Dining Room  (Room 395)
Day 2 — Friday, March 10, 2023 
Plenary Session
8:30–9:00Registration & Welcome Coffee
Koumentzelis Auditorium, Lindsay Hall, 3rd Floor, Bentley University, 175 Forest St, Waltham, MA, USA
9:00–9:15Opening Remarks 
Jana Hersch, Head of Corporate Scientific Engagement, Genedata, Boston, MA, USA
9:15–9:45Genedata Biologics at BMS: Moving the Data Biosphere into the Multiverse
Jeffrey Johnson, Scientific Associate Director, Bristol Myers Squibb, San Diego, CA, USA
9:45–10:15Genedata Bioprocess in the Time of COVID
Robert Hepler, Principal Scientist, Janssen, Spring House, PA, USA
10:15–10:45Digital Transformation at Boehringer Ingelheim
Rachel Kroe-Barrett, Executive Director, Biophysics, Boehringer Ingelheim, Ridgefield, CT, USA
10:45–11:15Break
11:15–12:15Panel Discussion
Learning from Data to Improve Predictions in Biotherapeutic R&D
The discussion will focus on the importance of data and digital in biopharma R&D, what works and what does not, and current trends. We would like to present diverse approaches across a spectrum of biopharma and biotech companies with a focus on best practices and emerging ways of working with information.
 
  • Barbara Brannetti, Director, Data Science, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, USA
  • Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA
  • Patrick Kaminker, Director Translational Biology, MacroGenics Inc., Rockville, MD, USA
  • Gilad Kaplan, Associate Director, Biologics Engineering, AstraZeneca, Gaithersburg, MD, USA
  • Kate Hardy, Director, Informatics and Technology, MOMA Therapeutics, Cambridge, MA, USA
 
12:15–2:00Lunch
LaCava Center, 3rd Floor, Executive Dining Room  (Room 395)
Breakout Sessions
 BIOLOGICS
Biotherapeutics Discovery		BIOPROCESS
Bioprocess Development		SCREENER
Assay Analysis & Management		PROFILER
Translational & Clinical Research		SELECTOR
NGS-Based Development & Biosafety
2:00–2:30

Protein Production & Analytics at Sanofi Large Molecule Research
Sonja Tierney, Sr. Associate Scientist, Sanofi, Cambridge, MA, USA

Chromatography Data Platform
Isabel Kolinko,
Scientific Consultant, Screener, Genedata, Basel, Switzerland

Christoph Freiberg,
Head of Science, Biologics, Genedata, Basel, Switzerland

In Search of COVID-19 Therapeutics:  Efficient Analysis of Single-Agent and Combination 
Lisa M. Aschenbrenner, Scientist – Primary Pharmacology, Pfizer, Croton, CT, USA 		Connecting Teams Through Data Federation
Marc Flesch, Head of Genedata Profiler, Genedata, Munich, Germany		A Closer Look to Genomic Integrity: Novel Technologies to Improve Detection and Quantification
Marco De Cecco, Director of Cytogenomics, Astellas IRM, Westborough, MA, USA
2:30–3:00Corralling Diverse OmniAb Antibody Repertoires with Phenotypic Screening and High Throughput Characterization
Bob Chen, Senior Director, Systems Engineering, OmniAb, Emeryville, CA, USA		Roundtable Discussion:
Smart Digitalization in Bioprocess Development		Roundtable Discussion:
It’s Time to Think About Automating Data Processes the Way We Automate Wet Lab Processes		Roundtable Discussion:
You Ask, We Answer		Sequencing to Support a Genetic Medicine Portfolio
Lawrence Thompson, Associate Research Fellow, Medicinal Sciences & BioTherapeutics PharmSci, Analytical R&D, Pfizer, Chesterfield, MO, USA 
3:00–3:30Break
3:30–4:00Genedata Biologics Product Roadmap
Christoph Freiberg, Head of Science, Biologics, Genedata, Basel, Switzerland

Selector Panel Discussion:
NGS as Multi-Attribute Method in CGT Analytical R&D

  • Jarrod Dean, Associate Director, NGS Leader, Genomic Medicine Unit, CMC, Sanofi, Framingham, MA, USA
  • Mehmet Karaca, Associate Director, Molecular Biology-Sequencing Gene Therapy QC, Sarepta Therapeutics, Andover, MA, USA
  • Marco De Cecco, Director of Cytogenomics, Astellas IRM, Westborough, MA, USA
  • Devon Ryan, Head of Scientific Consulting, Genedata Selector, Basel, Switzerland
 
4:00–4:30Closing Remarks & End of Symposium

 

See What You Missed – Partner Symposium Highlights

Check out highlights from the 8th Annual Genedata Biopharma Partner Symposium on March 23–24, 2022. Scientists and IT experts from 26 companies enjoyed meeting in Basel, Switzerland, hearing interesting presentations, and sharing experiences and best practices.

 

 

Agenda 2022

Participants in previous Genedata symposia have included the following customers

In addition to the excellent presentations, the many demo sessions and the chance to talk to other participants about their experiences with deployment, user adoption, integration, and other important topics faced when onboarding an enterprise end-to-end solution made the event extremely interesting and productive.

Bristol Myers Squibb

Lore Florin, Ph.D.
Director Antibody Generation

I’ve participated many times over the years and it’s exciting to see how the Genedata software platform has grown, as well as to get to meet the mix of scientists and IT managers joining from the many new pharma and biotech companies who adopt the platform each year.

Janssen

Ruo Steensma, Ph.D.
Senior Director, Research & Laboratory Platforms

Genedata is a critical software for our work so it’s great to come to the partner symposium and have a voice in how the product develops.

Sanofi

Senior Scientist